An Unrivaled Offering for
Your Healthcare Research
Our portfolio of more than 30 peer-reviewed
journals aims to provide a publishing opportunity
for all scientifically sound articles
For over 50 years, Adis journals have been publishing high-quality content for global healthcare audiences
Our journals span all therapeutic areas with a focus on drugs, devices, diagnostics, and other interventions. Adis journals provide healthcare researchers and practitioners with relevant and up-to-date information on the latest developments in disease management via a structured program of review and original research articles. The portfolio contains a number of high-impact journals that are leaders in their respective fields. Adis journals are led by expert Editors-in-Chief with advanced competency in a range of disciplines, including: clinical trials, pharmacokinetics, pharmacovigilance and drug safety, health economics and outcomes, and their respective therapeutic areas. This allows fast turn-around of pre-submission inquiries, manuscript assessment, and peer review.
Adis journals provide exceptional service by offering:
Our journal editors can provide expert pre-submission technical feedback on manuscripts (whether provided as a detailed article outline or a full manuscript) to ensure they are targeted at the most suitable journal within the portfolio. Manuscripts are treated as confidential and are only shared among our journal editors, as necessary.
If a manuscript is considered unsuitable for the journal to which it has been submitted, either before or after peer review, it can often be cascaded to a sister title within the Adis journals portfolio. Articles are only cascaded with the author‘s permission.
All Adis journals offer efficient peer review, with standard timelines ranging from 2 to 6 weeks (depending on the journal). Some journals also offer a VIP Service (for a processing fee) that guarantees peer review in 10 days.
Adis journals endorse the ICMJE/WAME/COPE Guidelines for Journal Editors, and encourage all manuscripts reporting sponsored research to comply with Good Publication Practice (GPP-3). Authors’ potential conflicts of interest and research/manuscript funding are clearly presented in each article.
A number of the Adis journals are fully open access, while others offer open-access publication of individual articles via the Springer Open Choice option. All journals provide open access with the CC BY-NC license, as standard.
All Adis journals have worldwide readership, including in Europe, the US and Asia. They are available to healthcare professionals as part of the Springer Nature global content packages. Most journals are indexed in major biomedical databases (Medline and/or PubMed), allowing readers worldwide to find published content.
Any article published in an Adis journal can be accompanied by a peer-reviewed Plain-Language Summary, which is intended to provide a succinct, simplified overview of the article to assist non-experts in understanding its content and overall implications.
Plain-language summaries can be submitted with the manuscript (no fee) or added afterwards (article processing fee to cover peer review and production). See Adis guidelines for digital features and plain-language summaries for more information.
Adis publishes definitive single-agent reviews providing readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas. These reviews are published in several of the high-impact Adis Premier journals.
All articles can host peer-reviewed digital features, such as slide sets, animations, videos and audioslides for extra educational value.